Phosphorylation of glycogen synthase kinase-3 β at serine 9 confers cisplatin resistance in ovarian cancer cells

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 657-662

  Cai, Guoqing ^a   Wang, Jian ^a   Xin, Xiaoyan ^a   Ke, Zunji ^b   Luo, Jia ^b,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin sensitivity; Glycogen synthase kinase 3 ; Ovarian carcinoma; p53

Indexed keywords

CISPLATIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN P53; SERINE; TP53 PROTEIN, HUMAN; TYROSINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CHEMISTRY; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; HUMAN; IC 50; METABOLISM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INHIBITORY CONCENTRATION 50; OVARIAN NEOPLASMS; PHOSPHORYLATION; SERINE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE;

EID: 38449116493     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.657     Document Type: Article

References (29)

1. Barnes MN, Grizzle WE, Grubbs CJ and Partridge EE: Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 52: 216-225, 2002.
2. Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G and Berns EM: Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6: 201, 2006.
3. Doble BW and Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003.
4. Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102, 2004.
5. Ougolkov AV and Billadeau DD: Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2: 91-100, 2006.
6. Vaisman A, Varchenko M, Said I and Chaney SG: Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27: 54-64, 1997.
7. Chen G, Bower KA, Ma C, Fang S, Thiele CJ and Luo J: Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18: 1162-1164, 2004.
8. Jones NA, Turner J, McIlwrath AJ, Brown R and Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 53: 819-826, 1998. (Pubitemid 28244068)
9. Wang X, Wang B, Fan Z, Shi X, Ke ZJ and Luo J: Thiamine deficiency induces endoplasmic reticulum stress in neurons. Neuroscience 144: 1045-1056, 2007.
10. Perez RP, Perez KM, Handel LM and Hamilton TC: In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 29: 430-434, 1992.
11. De Sarno P, Li X and Jope RS: Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164, 2002.
12. Zhang F, Phiel CJ, Spece L, Gurvich N and Klein PS: Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278: 33067-33077, 2003.
13. Yazlovitskaya EM, DeHaan RD and Persons DL: Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 283: 732-737, 2001.
14. Song L, De Sarno P and Jope RS: Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 277: 44701-44708, 2002. (Pubitemid 36159060)
15. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Ruiz-Ruiz C, Cadoret A, Capeau J and Desbois-Mouthon C: GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res 300: 354-364, 2004.
16. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Cadoret A, Capeau J and Desbois-Mouthon C: GSK-3β reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Int J Oncol 27: 215-222, 2005.
17. King TD, Bijur GN and Jope RS: Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 919: 106-114, 2001.
18. Li X, Bijur GN and Jope RS: Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4: 137-144, 2002.
19. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M, Koumenis C, Taya Y, Yoshimura A and Koromilas AE: Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev 18: 261-277, 2004.
20. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV and Jope RS: Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci USA 99: 7951-7955, 2002.
21. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X and Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278: 48872-48879, 2003.
22. Kulikov R, Boehme KA and Blattner C: Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 25: 7170-7180, 2005. (Pubitemid 41105913)
23. Ghosh JC and Altieri DC: Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res 11: 4580-4588, 2005.
24. Gotoh J, Obata M, Yoshie M, Kasai S and Ogawa K: Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis 24: 435-442, 2003.
25. Leis H, Segrelles C, Ruiz S, Santos M and Paramio JM: Expression, localization, and activity of glycogen synthase kinase 3beta during mouse skin tumorigenesis. Mol Carcinog 35: 180-185, 2002. (Pubitemid 36056712)
26. Mulholland DJ, Dedhar S, Wu H and Nelson CC: PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 25: 329-337, 2006. (Pubitemid 43117618)
27. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 334: 1365-1373, 2005.
28. Rask K, Nilsson A, Brännström M, Carlsson P, Helberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β. Br J Cancer 89: 1298-1304, 2003.
29. Cao Q, Lu X and Feng YJ: Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 16: 671-677, 2006. (Pubitemid 44091443)